Trial Profile
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 24 Oct 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 24 Oct 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 24 Oct 2023 Status changed from recruiting to active, no longer recruiting.